| From: scaram(o)uche | 3/11/2010 9:14:03 AM | | | | | | Jack Lief of Arena Pharm. said in early January that Ortho McNeil was moving a novel molecule forward in clinical testing for type II diabetes. It would only be a phase II study, but it's directed against a novel target (GPR119) and a huge market. While not a material disclosure for JNJ, it certainly is one for Arena. Does anybody here know of any FORMAL notice that Ortho has moved this molecule forward in testing? Thanks for any help!
If you're interested, here are links. But they'll require registration to get to them, I believe..... the key part is at 16:25......
metameetings.com
metameetings.com
(links probably won't work without registration and login)
"so, so, let me just mention that Ortho McNeil Johnson and Johnson is moving our type 2 diabetes compound APD597 forward and we've received over $50 million from JNJ we hope to have double digit royalties as well as significant milestones in the future." |
| | JNJ-Super company, Super stock! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: Sr K | 9/16/2011 7:01:42 PM | | | | | | MANAGEMENT | SEPTEMBER 16, 2011, 5:34 P.M. ET
J&J Negotiated Over Executive's Departure
By JOANN S. LUBLIN And JONATHAN D. ROCKOFF
Johnson & Johnson's insistence on enforcing a non-compete agreement to keep senior executive Michael Mahoney from joining archrival Boston Scientific Corp. as chief executive led to unusual employment terms at the medical device maker, according to people familiar with the matter.
J&J agreed to allow Mr. Mahoney to join Boston Scientific only after the company promised the 46-year-old won't supervise competing businesses or become its chief executive until late 2012 and agreed to have its general counsel personally monitor compliance, those people said.
Boston Scientific said Tuesday that Mr. Mahoney, who had been heading J&J's medical devices and diagnostics group, would become its president next month and CEO effective on Nov. 1, 2012. In the interim, Hank Kucheman, who has been running Boston Scientific's defibrillator business, will serve as chief executive. Current CEO Ray Elliott is retiring.
wsj.com |
| | JNJ-Super company, Super stock! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: zax | 12/1/2014 1:44:57 PM | | | | | | | Sold 4/5 of my JNJ today; 100%+ gain. Nice run. With Remicade coming off of patent protection, I'm seeing the end of a great run on the horizon. |
| | JNJ-Super company, Super stock! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: Sr K | 2/23/2016 12:18:42 PM | | | | | | Reuters
2/23/2016
J&J must pay $72 million for cancer death linked to talcum powder: lawyers
By Jonathan Stempel
(Reuters) - Johnson & Johnson (JNJ) was ordered by a Missouri state jury to pay $72 million of damages to the family of a woman whose death from ovarian cancer was linked to her use of the company's talc-based Baby Powder and Shower to Shower for several decades.
In a verdict announced late Monday night, jurors in the circuit court of St. Louis awarded the family of Jacqueline Fox$10 million of actual damages and $62 million of punitive damages, according to the family's lawyers and court records.
The verdict is the first by a U.S. jury to award damages over the claims, the lawyers said.
Johnson & Johnson (JNJ) faces several hundred lawsuits claiming that it, in an effort to boost sales, failed for decades to warn consumers that its talc-based products could cause cancer.
Fox, who lived in Birmingham, Alabama, claimed she used Baby Powder and Shower to Shower for feminine hygiene for more than 35 years before being diagnosed three years ago with ovarian cancer. She died in October at age 62.
Jurors found Johnson & Johnson (JNJ) liable for fraud, negligence and conspiracy, the family's lawyers said. Deliberations lasted four hours, following a three-week trial.
Jere Beasley, a lawyer for Fox's family, said Johnson & Johnson (JNJ) "knew as far back as the 1980s of the risk," and yet resorted to "lying to the public, lying to the regulatory agencies." He spoke on a conference call with journalists.
Carol Goodrich, a Johnson & Johnson (JNJ) spokeswoman, said: "We have no higher responsibility than the health and safety of consumers, and we are disappointed with the outcome of the trial. We sympathize with the plaintiff's family but firmly believe the safety of cosmetic talc is supported by decades of scientific evidence."
In October 2013, a federal jury in Sioux Falls, South Dakota found that plaintiff Deane Berg'suse of Johnson & Johnson's (JNJ) body powder products was a factor in her developing ovarian cancer. Nevertheless, it awarded no damages, court records show.
Valeant Pharmaceuticals International Inc (VRX) now owns the Shower to Shower brand but was not a defendant in the Fox case.
The case is Hogans et al v. Johnson & Johnson (JNJ) et al, Circuit Court of the City of St. Louis, Missouri, No. 1422-CC09012. |
| | JNJ-Super company, Super stock! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Sr K | 6/16/2017 8:35:15 AM | | | | | | 3:51 am Johnson & Johnson completes acquisition of Actelion ( ALIOY) ( JNJ) :
Johnson & Johnson ( JNJ) announced the completion of the acquisition of Actelion ( ALIOY) for a total purchase price of ~$30 bln in cash.
Actelion will now become part of the Janssen Pharmaceutical Companies of Johnson & Johnson.In connection with the completion of the public tender offer, Actelion has spun off its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, Idorsia |
| | JNJ-Super company, Super stock! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: ChristophMcLee | 7/5/2017 12:58:04 PM | | | | | | JNJ second quarter earnings are expected in two weeks, and atmosphere is intense, especially with the completion of Actelion acquisition. JNJ posted a decent Q1 with 2% sales growth and 6% adjusted EPS growth.
Hoping to see more leverage in the coming quarter also! |
| | JNJ-Super company, Super stock! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
